SEC filing record
Primary Source · SEC.gov

Benitec Biopharma Inc.

2024 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2024-04-25Last filing 2024-04-25

Raised

$40M

Investors

17

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Benitec Biopharma Inc. is a Delaware corporation that filed a Form D with the SEC on April 25, 2024 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Benitec Biopharma Inc. reported $40,000,018 sold from 17 investors of a $40,000,018 total offering as of the Form D filed April 25, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Leerink Partners LLC (CRD 39011), associated with None; Citizens JMP Securities, LLC (CRD 22208), associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $2,400,001 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 3940 Trust Way, Hayward, CA 94545.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001808898
Entity NameBenitec Biopharma Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address3940 Trust Way, Hayward, CA 94545
Phone(510) 780-0819
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateApril 22, 2024
Filing DateApril 25, 2024
Accession Number0001012975-24-000183
Total Offering Amount$40,000,018
Total Amount Sold$40,000,018
Amount Remaining$0
Total Investors17
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$2,400,001 (to Leerink Partners LLC and 1 other)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)CA
Amendment CountOriginal filing only

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

1

latest Apr 25, 2024

Critical / warning

0 / 0

1 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

closed

Latest event New filer · Apr 25, 2024

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 1 filing event with values and deltas, latest 2024-04-25, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Jerel Banks

Executive Officer, Director · Hayward, CA

Megan Boston

Executive Officer, Director · Hayward, CA

J. Kevin Buchi

Director · Hayward, CA

Peter Kevin Francis

Director · Hayward, CA

Edward Kevin Smith

Director · Hayward, CA

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Leerink Partners LLCCRD 39011 on BrokerCheck

Associated broker-dealer: None · Boston, MA · Soliciting in all states

Citizens JMP Securities, LLCCRD 22208 on BrokerCheck

Associated broker-dealer: None · San Francisco, CA · Soliciting in all states

Questions About Benitec Biopharma Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Benitec Biopharma Inc.?

Benitec Biopharma Inc. is a Delaware corporation that filed a Form D with the SEC on April 25, 2024 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is Benitec Biopharma Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Benitec Biopharma Inc. filed a Form D with the SEC on April 25, 2024 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $40,000,018 sold to 17 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Benitec Biopharma Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Benitec Biopharma Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Benitec Biopharma Inc. raised?

Benitec Biopharma Inc. reported $40,000,018 sold from 17 investors of a $40,000,018 total offering as of the Form D filed April 25, 2024.

Who can invest in Benitec Biopharma Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Benitec Biopharma Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Benitec Biopharma Inc. and how are they paid?

The Form D names Leerink Partners LLC (CRD 39011), associated with None; Citizens JMP Securities, LLC (CRD 22208), associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $2,400,001 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Benitec Biopharma Inc.?

The Form D lists 5 related persons: Jerel Banks, executive officer, director; Megan Boston, executive officer, director; J. Kevin Buchi, director; Peter Kevin Francis, director; Edward Kevin Smith, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Benitec Biopharma Inc. located?

The issuer's address on its SEC filings is 3940 Trust Way, Hayward, CA 94545. Its phone number of record is (510) 780-0819. It is organized under the laws of Delaware.

How long is the Benitec Biopharma Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is Benitec Biopharma Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.